Mesoblast Limited (MESO,MSB.AX) announced that the U.S. Food and Drug Administration has granted its allogeneic cell therapy Revascor (rexlemestrocel-L) a Rare Pediatric Disease Designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome or HLHS, a potentially life threatening congenital heart condition.
MESO closed Thursday's regular trading at $1.72 down $0.02 or 1.15%. But in the after-hours trading the stock gained $0.38 or 22.09%.
Rare Pediatric Disease Designation is granted by the FDA for certain serious or life-threatening diseases which primarily affect children. On FDA approval of a Biologics Licensing Application (BLA) for REVASCOR for the treatment of HLHS, Mesoblast may be eligible to receive a Priority Review Voucher (PRV) that can be redeemed for any subsequent marketing application or may be sold or transferred to a third party.
hypoplastic left heart syndrome is a severe congenital heart disease in which the left side of the heart does not fully develop and effective pumping of oxygenated blood by the left ventricle to the rest of the body is reduced. Without immediate surgery after birth, the prognosis is dismal with HLHS overall being responsible for 25% to 40% of all neonatal cardiac mortality.For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.